Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
01:22pm, Tuesday, 03'rd Jun 2025
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outpe
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
11:26am, Tuesday, 03'rd Jun 2025
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Buy, Sell, Or Hold PFE Stock At $23?
10:00am, Tuesday, 03'rd Jun 2025
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-
3 Low-Priced Dividend Stocks Paying Over 5% Right Now
09:05am, Tuesday, 03'rd Jun 2025
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June
03:06am, Tuesday, 03'rd Jun 2025
There are a lot of strategies investors can employ on Wall Street to grow their wealth. With thousands of publicly traded companies and more than 3,000 exchange-traded funds (ETFs) to choose from, the
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
04:00pm, Monday, 02'nd Jun 2025
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc
Why BioNTech Stock Soared Today
01:38pm, Monday, 02'nd Jun 2025
BioNTech (BNTX 20.19%), one of the companies made famous for its role developing vaccines with Pfizer (PFE -0.47%) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
10:00am, Monday, 02'nd Jun 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
10:00am, Monday, 02'nd Jun 2025
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, r
Terrible News for Pfizer Stock Investors
09:15am, Sunday, 01'st Jun 2025
The past three years have been challenging for Pfizer (PFE 0.11%). Revenue and earnings have moved in the wrong direction, as has the company's share price.
2 High-Yield Dividend Stocks Yielding Over 6% That'll Pay You to Wait
07:45am, Sunday, 01'st Jun 2025
High-yielding dividend stocks may not be the ticket to superior returns, but they can rank pretty high on the list of nice-to-haves for investors in retirement or those who could use a bit of extra fi
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
10:01am, Saturday, 31'st May 2025
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it ca
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
08:06am, Saturday, 31'st May 2025
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
12:23pm, Friday, 30'th May 2025
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encoraf
